Physician profile
Stephen Anderson
NPI 1619931490
$1,385.98
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $404 · 2021: $340 · 2022: $32.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.03 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $232.77 | 2019-2020 | |
| Ibsa Pharma INC. | $143.87 | 2019-2022 | |
| Abbott Laboratories | $139.80 | 2019 | |
| Companion Medical, INC. | $127.75 | 2019-2020 | |
| Medtronic Minimed, INC. | $98.76 | 2019 | |
| Pfizer INC. | $55.71 | 2021 | |
| Arbor Pharmaceuticals, INC. | $55.21 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $49.11 | 2020 | |
| Becton, Dickinson and Company | $43.47 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $40.25 | 2020-2021 | |
| Galen US INC | $25.15 | 2019 | |
| Novo Nordisk INC | $24.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.69 | 2021 | |
| Insulet Corporation | $19.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $18.81 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.58 | 2019 | |
| Vistapharm, INC. | $13.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.